Not Yet Recruiting PHASE1 Interventional 2-arm
NCT05112822
Testing Obeticholic Acid (OCA) for Familial Adenomatous Polyposis (FAP)
MDA20-01-01: A Phase IIa, Placebo-Controlled, Randomized Study of Daily Obeticholic Acid (OCA) to Reduce Intestinal Polyp Burden in Familial Adenomatous Polyposis (FAP)
Sponsor: M.D. Anderson Cancer Center
Conditions
Familial Adenomatous Polyposis
Interventions
Obeticholic Acid Placebo
Updated 1 time since 2021 Last updated: Nov 18, 2021 Started: Mar 31, 2022 Primary completion: Feb 28, 2024 Completion: Feb 28, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This PHASE1 trial investigates Familial Adenomatous Polyposis and is currently actively recruiting participants. M.D. Anderson Cancer Center leads this study, which shows 1 recorded version since 2022 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE1
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- M.D. Anderson Cancer Center
Data source: M.D. Anderson Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .